Development trends for new cancer therapeutics and vaccines

Drug Discovery Today
Janice M Reichert, Julia B Wenger

Abstract

Global commercial development of cancer treatments has dramatically increased over the past 15 years. To assess trends in the process, we analyzed data for 1111 candidates that entered clinical study during 1990-2006. Our results show that although the average number of therapeutic candidates entering clinical study per year more than doubled, the US approval success rate was low (8%) during the period. The therapeutics took seven years on average to go through the clinical and US approval phases, but cancer vaccines have yet to gain any US approvals. These results indicate that improvement in the efficiency of the development process for innovative cancer treatments is needed.

Associated Clinical Trials

Citations

Oct 17, 2012·Analytical and Bioanalytical Chemistry·Michael Groessl, Christian G Hartinger
Jun 3, 2011·Gene Therapy·A G BaderP Lammers
Jul 12, 2012·Nature Biotechnology·Mallika Singh, Napoleone Ferrara
Nov 9, 2010·Nature Biotechnology·Joshua Cohen, William Looney
Sep 9, 2010·Nature Medicine·Terry Van Dyke
Jun 11, 2010·Nature Reviews. Cancer·Timothy A YapJohann S de Bono
Nov 15, 2008·Nature Reviews. Drug Discovery·Ian Walker, Herbie Newell
Oct 15, 2009·The Cancer Journal·Daniel S W TanPaul Workman
Mar 19, 2013·Nanoscale Research Letters·Muniza ZahidSung Ha Park
Aug 25, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Darren R Flower
Sep 17, 2011·Expert Review of Vaccines·Erika Jensen-Jarolim, Josef Singer
Mar 10, 2012·Expert Opinion on Drug Delivery·Mahfoozur RahmanFiroz Anwar
Nov 18, 2008·Expert Opinion on Investigational Drugs·Robert Williams
Jun 22, 2012·Expert Opinion on Drug Discovery·Jessie M Wu, Carolyn A Staton
Apr 3, 2012·Drug Discovery Today·Francesca Milletti
Jan 12, 2011·Biochemical and Biophysical Research Communications·Hadas Sneh-Edri, David Stepensky
Sep 11, 2010·Journal of Pharmaceutical and Biomedical Analysis·Jonas WinterThomas Bunte
Aug 24, 2010·Drug Discovery Today·Ranjita MisraSanjeeb K Sahoo
Jun 23, 2009·Biochemical Pharmacology·Raymond J WinquistBrinley F Furey
Feb 17, 2009·Bioorganic & Medicinal Chemistry·Roberto MartínezMa Teresa Ramírez-Apan
Dec 10, 2008·Drug Discovery Today·Lois A Lampson
Nov 18, 2008·Acta Biomaterialia·Monica C Branco, Joel P Schneider
Jan 24, 2009·Biochemical Pharmacology·Christian Bailly
May 7, 2011·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·E Jensen-Jarolim, J Singer
Oct 15, 2013·The Journal of Pathology·Meghna Das ThakurMallika Singh
Mar 13, 2014·Internal Medicine Journal·D J KarikiosM R Stockler
Oct 1, 2011·Expert Opinion on Investigational Drugs·Robert Williams
Jan 5, 2010·MAbs·Joshua Cohen, Andrew Wilson
Jan 22, 2015·Biomarkers in Medicine·Daniel A RubingerJayson L Parker
Mar 18, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laetitia E LambertsElisabeth G E de Vries
Mar 27, 2018·Chemical Biology & Drug Design·Sunil Dutt DurgapalShubhangi S Soman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Related Papers

Nature Reviews. Drug Discovery
Ismail Kola, John Landis
Nature Reviews. Drug Discovery
Janice M Reichert, Viia E Valge-Archer
Nature Reviews. Cancer
Bruce A Chabner, Thomas G Roberts
Nature Reviews. Drug Discovery
Alexander KambChristoph Lengauer
Nature Reviews. Drug Discovery
Anthony W PurcellJamie Rossjohn
© 2021 Meta ULC. All rights reserved